Based in California, SP Investment Fund focuses on socially positive real estate and emerging technology investments. In addition to being an active investor, developer and renovator of affordable housing for low and very low income seniors, families and disabled individuals, SP Investment Fund has also made significant investments in emerging health sciences and biotechnology companies, including Coral Genomics.
Based in San Carlos, California, Coral Genomics is a biotech startup that has designed a proprietary platform to accelerate drug development and deployment by performing experiments on a vast database of cells and measuring and finding correlations with DNA and RNA expressions. Without Coral Genomic’s technology, such big data analysis has heretofore not been economically viable. Coral Genomics’ drug-response prediction system is a three-step process, which includes targeting variability, comparing it to other patients, and recommending treatment strategies.
Coral utilizes the patient’s genetic profile and measures RNA expression to determine how likely the cells within the body will react to a specific drug. The profile consists of characteristics unique to the DNA of an individual or population, derived from the analysis of small samples of body tissues or fluids. As the patient’s susceptibility to a particular drug becomes clear, Coral can begin to perform experiments that will reduce variation across patients.
Currently in its first year, Coral Genomics believes that this new platform will improve the efficiency of clinical trials and healthcare delivery.
